Aplidin – Dexamethasone in Relapsed/Refractory Myeloma

Inclusion Criteria:

Age ≥ 18 years.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2
Life expectancy ≥ 3 months.
Patients previously diagnosed with multiple myeloma
Patients must have relapsed or relapsed and refractory multiple myeloma (MM) after at least three but not more than six prior therapeutic regimens for MM, including treatment-for-multiple-myeloma-induction-therapy/" >induction therapy and stem cell transplant in candidate patients, which will be considered as only one regimen.
Patients must have received previous bortezomib-containing and lenalidomide-containing regimens (or thalidomide where lenalidomide is not available)
Women must have a negative serum pregnancy test
Voluntarily signed and dated written informed consent

Exclusion Criteria:

Concomitant diseases/conditions
Women who are pregnant or breast feeding.
Concomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against MM
Known hypersensitivity to any involved study drug or any of its formulation components